NRx Pharmaceuticals (NASDAQ:NRXP) and Indivior (OTCMKTS:INVVY) Critical Analysis

Indivior (OTCMKTS:INVVY) and NRx Pharmaceuticals (NASDAQ:NRXP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Indivior and NRx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Indivior	N/A	N/A	N/A
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

Valuation and Earnings

This table compares Indivior and NRx Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$791.00 million	3.81	$205.00 million	$1.05	20.81
NRx Pharmaceuticals	$3.39 million	43.24	-$28.62 million	($0.55)	-6.16

Indivior has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Indivior has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of Indivior shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Indivior and NRx Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0	0	1	0	3.00
NRx Pharmaceuticals	2	0	5	0	2.43

Indivior currently has a consensus target price of $50.00, indicating a potential upside of 128.88%. NRx Pharmaceuticals has a consensus target price of $34.50, indicating a potential upside of 917.70%. Given NRx Pharmaceuticals’ higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Indivior.

Summary

Indivior beats NRx Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Indivior

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.